Medicine 2019 June [Link] Zan X, Wang Y, Shi J, Zhao L, Zhao Y, Liu R, Zhou Y, Wan Y Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly invasive tumor caused primarily by asbestos exposure. In recent decades, the incidence of MPM has shown an increasing trend, posing a great threat to human health. […]
June 25, 2019
Annals of the American Thoracic Society 2019 June 12 [Link] Bibby AC, Halford P, De Fonseka D, Morley AJ, Smith S, Maskell NA Abstract RATIONALE: Non-expandable lung is a recognised phenomenon that can create management challenges in mesothelioma. Its prevalence and clinical importance are unknown. OBJECTIVE: The aim of this study was to describe the […]
June 24, 2019
Journal of Thoracic Disease 2019 April [Link] Nelson DB, Rice DC, Mitchell KG, Tsao AS, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Gomez DR, Mehran RJ, Sepesi B Abstract BACKGROUND: Multimodality therapy may prolong survival among resectable malignant pleural mesothelioma (MPM). However, the role of adjuvant radiation remains controversial. We […]
June 21, 2019
Journal of Thoracic Disease 2019 April [Link] Rodríguez-Cid JR, García-Acevedo O, Benjamin-Contreras J, Bonilla-Molina D, Flores-Mariñelarena RR, Martínez-Barrera L, Alatorre-Alexander JA, Sanchez-Ríos CP, Flores-Soto MDR, Santillan-Doherty PJ, Peña-Mirabal ES Abstract BACKGROUND: Overexpression of estrogen receptors in malignant pleural mesothelioma has shown an independent relation with a better prognosis of survival, and the use of selective […]
June 20, 2019
Clinical Cancer Research 2019 June 7 [Link] Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V Abstract PURPOSE: The IFCT-GFPC-0701 MAPS Phase III trial […]
June 19, 2019
Carcinogenesis 2019 June 5 [Link] Gillezeau C, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E Abstract Malignant Pleural Mesothelioma (MPM) is a rare by aggressive cancer, and early detection is associated with better survival. Mesothelin, fibulin-3, and osteopontin have been suggested as screening biomarkers. The study conducted a meta-analysis of the mean […]
June 18, 2019
Clinical Cancer Research 2019 June 4 [Link] Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor […]
June 17, 2019
Cytopathology 2019 June 5 [Link] Önder S, Özogul E, Koksal D, Sarinc Ulasli S, Firat P, Emri S Abstract OBJECTIVE: The aim of this study was to investigate the utility of BAP1, GLUT-1 and desmin expression by immunohistochemistry in the discrimination between reactive and malignant mesothelial proliferations. METHODS: A total of 88 biopsies and 30 […]
June 14, 2019
Pathology Research and Practice 2019 May 22 [Link] Wang H, Herath C Abstract Signet ring cell mesothelioma is a rare variant of epithelioid mesothelioma with limited cases published. It has a male predilection and most commonly occurs on pleura; it can also arise in the peritoneal cavity. The signet ring cell morphology can pose a […]
June 11, 2019
BMC Cancer 2019 May 28 [Link] Kettunen E, Savukoski S, Salmenkivi K, Böhling T, Vanhala E, Kuosma E, Anttila S, Wolff H Abstract BACKGROUND: Deletion of the CDKN2A locus is centrally involved in the development of several malignancies. In malignant pleural mesothelioma (MPM), it is one of the most frequently reported genomic alteration. MPM is […]
June 10, 2019